Editorial
An Established Technology Gets a New Application: Reimplantation of Autologous Ovarian Tissue to Treat Menopausal Symptoms
BM Petrikovsky1*, EV Zharov2 and M Cohen3
1Chairman of Obstetrics and Gynecology, Nassau University Medical Center, USA
2Russian Federation Academy of Science, Russia
3Attending Emeritus, Hartford Hospital, USA
BM Petrikovsky, Professor and former Chairman of Obstetrics and Gynecology, Nassau University Medical Center, USA.
Received Date: April 12, 2019; Published Date: April 18, 2019
Abstract
In 1954 and 1956, Deanesly [1] and Green, et al. [2] were one of the first to experiment with the freezing and thawing of animal ovarian tissue. In the first half of the 20th century, the art of tissue cryopreservation was at its infancy with glycerol being the only cryoprotectant available [3]. Glycerol is a poor cryoprotectant and, therefore, early research showed very limited success [4]. Additional cryoprotectants became available during the 1990s leading to successful ovarian tissue cryopreservation, transplantation, and resumption of fertility studies in animals and humans [3,5,6].
-
BM Petrikovsky, EV Zharov, M Cohen. An Established Technology Gets a New Application: Reimplantation of Autologous Ovarian Tissue to Treat Menopausal Symptoms. 2(2): 2019 WJGWH.MS.ID.000534.
-
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.